Safety and Performance of UCon Bar Electrode for the Treatment of Overactive Bladder (OAB) and Bowel Dysfunction (BD)

Last updated: May 3, 2024
Sponsor: InnoCon Medical
Overall Status: Active - Recruiting

Phase

N/A

Condition

Urinary Incontinence

Gastrointestinal Diseases And Disorders

Rectal Disorders

Treatment

UCon-Bar

Clinical Study ID

NCT06091566
DK_FEAS_02
  • Ages > 18
  • Female

Study Summary

UCon is a medical device for treatment of the symptoms of overactive bladder (OAB) and bowel dysfunction (BD). It electrically stimulates the DGN through the skin to obtain modulated behaviour of the bladder/bowel musculature e.g., suppress undesired bladder/bowel activity to relieve the symptoms of the patient.

This clinical investigation is designed as a single-arm, prospective, multi-centre, and early feasibility study.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Participant is female
  2. Participant is ≥ 18 years of age.
  3. Participant is diagnosed with OAB or BD. OAB: Urinary urgency usually with one or more of the following: i. Urinary urgency incontinence (≥1 per/week). ii. Urinary frequency (≥8 voiding/daywithout polyuria). iii. Nocturia (≥2 voiding/night without nocturnal polyuria). BD: One or more of the following: i. Faecal urgency (≥3 urgencies pr. week) together with registration of urgency in St.Mark´s and a St. Mark´s score ≥9. ii. Faecal incontinence (urge/passive) (≥1 per/week).
  4. Participant is able to communicate, provide feedback, understand and followinstructions during the course of the investigation, including using the device athome.

Exclusion

Exclusion Criteria:

  1. Participant is medically unstable (acute illness or complication of a chroniccondition, apart from the OAB or BD, that might affect the participants´ participationin the investigation).
  2. Participant has an active infection in the genital area.
  3. Participant has an implanted pacemaker, implantable drug pump or other active medicaldevices (any medical device that uses electrical energy or other sources of power tomake it function).
  4. Participant is pregnant, nursing or planning a pregnancy (to be confirmed with anegative pregnancy test). Women of childbearing potential must maintain effectivecontraception during the clinical investigation.
  5. Participant is enrolled or planning to enrol in another conflicting clinicalinvestigation or was enrolled in an investigational drug trial or medical deviceinvestigation within four weeks of enrolment.
  6. Participant has neuropathy to a degree that is presumed to diminish the effect of theelectrical stimulation.
  7. Participant has a history of cancer in the pelvic region, are currently receivingcancer treatment, or has received radiation therapy in the pelvic region.
  8. Participant has addictive behaviour defined as the abuse of alcohol, cannabis,opioids, or other intoxicating drugs.
  9. Participant does not speak or understand Danish.
  • The following contraception is considered effective: Intrauterine device,hormonal contraceptives such as birth control pills, implants, contraceptivepatch, vaginal ring, and contraceptive injection.

Study Design

Total Participants: 20
Treatment Group(s): 1
Primary Treatment: UCon-Bar
Phase:
Study Start date:
January 12, 2024
Estimated Completion Date:
January 01, 2026

Study Description

The overall purpose of the current clinical investigation is to evaluate the medical device with a UCon-Bar Electrode with respect to its initial safety and device performance in a cohort of 20 female patients with OAB/BD over a period of 12 weeks.

The investigation consists of two periods: a screening period and an intervention period.

During the screening period, the participants will be using UCon with a Patch Electrode and complete a 4 week stimulation period at home. The screening period will determine if participants fulfil the criteria to participate in the intervention period.

During the intervention period, the UCon Bar Electrode will be inserted in the clitoral hood. After a recovery period (4-8 weeks), the participants will be using UCon with the Bar Electrode and complete wither a 4 week or a 12 week stimulation period at home.

Connect with a study center

  • Aarhus University Hospital

    Aarhus, 8200
    Denmark

    Active - Recruiting

  • Herlev Hospital

    Herlev, 2730
    Denmark

    Active - Recruiting

  • Odense University Hospital

    Odense, 5000
    Denmark

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.